Several brokerages have updated their recommendations and price targets on shares of BTG plc (LON: BTG) in the last few weeks:

  • 9/21/2017 – BTG plc had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a GBX 775 ($10.28) price target on the stock.
  • 9/20/2017 – BTG plc had its “hold” rating reaffirmed by analysts at Peel Hunt. They now have a GBX 680 ($9.02) price target on the stock.
  • 9/20/2017 – BTG plc had its “buy” rating reaffirmed by analysts at Numis Securities Ltd. They now have a GBX 900 ($11.94) price target on the stock.
  • 9/18/2017 – BTG plc had its “neutral” rating reaffirmed by analysts at J P Morgan Chase & Co.
  • 8/30/2017 – BTG plc had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a GBX 800 ($10.61) price target on the stock.
  • 8/9/2017 – BTG plc had its “buy” rating reaffirmed by analysts at Numis Securities Ltd. They now have a GBX 900 ($11.94) price target on the stock.

Shares of BTG plc (BTG) opened at 691.50 on Thursday. The firm’s market capitalization is GBX 2.66 billion. BTG plc has a 12-month low of GBX 528.36 and a 12-month high of GBX 738.50. The company’s 50-day moving average is GBX 680.17 and its 200-day moving average is GBX 662.08.

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.

Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with MarketBeat.com's FREE daily email newsletter.